Literature DB >> 18346244

Economic aspects of travelers' diarrhea.

Mathyas Wang1, Thomas D Szucs, Robert Steffen.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18346244     DOI： 10.1111/j.1708-8305.2008.00189.x

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  11 in total

1.  A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Authors:  Clayton Harro; David Sack; A Louis Bourgeois; R Walker; Barbara DeNearing; Andrea Feller; Subhra Chakraborty; Charlotte Buchwaldt; Michael J Darsley
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

Review 2.  Commercializing diarrhea vaccines for travelers.

Authors:  Rosa López-Gigosos; Marina Segura-Moreno; Rosa Díez-Díaz; Elena Plaza; Alberto Mariscal
Journal:  Hum Vaccin Immunother       Date:  2014-02-04       Impact factor: 3.452

Review 3.  Advances in the treatment of travelers' diarrhea.

Authors:  Mercedes Paredes-Paredes; Jose Flores-Figueroa; Herbert L Dupont
Journal:  Curr Gastroenterol Rep       Date:  2011-10

4.  The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Authors:  Michael J Darsley; Subhra Chakraborty; Barbara DeNearing; David A Sack; Andrea Feller; Charlotte Buchwaldt; A Louis Bourgeois; Richard Walker; Clayton D Harro
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

Review 5.  Clinical implications of enteroadherent Escherichia coli.

Authors:  Margarita M P Arenas-Hernández; Ygnacio Martínez-Laguna; Alfredo G Torres
Journal:  Curr Gastroenterol Rep       Date:  2012-10

Review 6.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

7.  Vaccination strategies to combat an infectious globe: oral cholera vaccines.

Authors:  Rosa M López-Gigosos; Elena Plaza; Rosa M Díez-Díaz; Maria J Calvo
Journal:  J Glob Infect Dis       Date:  2011-01

8.  Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products.

Authors:  Khandra T Sears; Sharon M Tennant; Mardi K Reymann; Raphael Simon; Nicky Konstantopoulos; William C Blackwelder; Eileen M Barry; Marcela F Pasetti
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

9.  Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

Authors:  Rosa López-Gigosos; Pedro Garcia-Fortea; Maria J Calvo; Emilia Reina; Rosa Diez-Diaz; Elena Plaza
Journal:  BMC Infect Dis       Date:  2009-05-16       Impact factor: 3.090

10.  Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea: a prospective cohort study.

Authors:  Rosa López-Gigosos; Magda Campins; María J Calvo; Santiago Pérez-Hoyos; Javier Díez-Domingo; Luis Salleras; María T Azuara; Xavier Martínez; José M Bayas; Josep M Ramón Torrell; María A Pérez-Cobaleda; María E Núñez-Torrón; Lydia Gorgojo; Magdalena García-Rodríguez; Rosa Díez-Díaz; Luis Armadans; Concepción Sánchez-Fernández; Teresa Mejías; Cristina Masuet; Rafael Pinilla; Nieves Antón; Pilar Segarra
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.